Hepcidin Mimetic in Patients With Polycythemia Vera
Status:
Active, not recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study with an open-label dose escalation phase followed by a blinded
withdrawal phase and an open label extension. The study is designed to monitor the PTG-300
safety profile and to obtain preliminary evidence of efficacy of PTG-300 for the treatment of
phlebotomy-requiring polycythemia vera.
Phase:
Phase 2
Details
Lead Sponsor:
Protagonist Therapeutics Protagonist Therapeutics, Inc.